DGAP-News: Myoscience to Present at the Canaccord Genuity Musculoskeletal Conference

| Source: EQS Group AG
DGAP-News: myoscience /
Myoscience to Present at the Canaccord Genuity Musculoskeletal

25.02.2014 / 13:00


REDWOOD CITY, Calif., 2014-02-25 13:00 CET (GLOBE NEWSWIRE) --
California based myoscience, inc., developers of the iovera*(r) system for the
treatment of peripheral nerve conditions, announced today that Clint Carnell,
Chairman and Chief Executive Officer, has been invited to make a presentation
at the Canaccord Genuity Musculoskeletal Conference, which will be held on
Tuesday, March 11, 2014 at 10:00 am CDT at the Sheraton New Orleans. 


Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. Focused
Cold Therapy is the patented technology delivered by the iovera* system. The
iovera* system is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions,
and is indicated in the United States for use in pain management and general
surgical use. For more information, please visit www.myoscience.com. 

The myoscience logo is available at

(c) 2014 myoscience. All rights reserved. iovera* and Focused Cold Therapy are
trademarks of myoscience. 

         Peter Osborne / posborne@myoscience.com
News Source: NASDAQ OMX

End of Corporate News


25.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English        
Company:     myoscience     
             United States  
ISIN:        US9902131674   
End of News    DGAP News-Service  
254240 25.02.2014